Drugs in the Pipeline
Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.
News
The systematic review and meta-analysis included a broad range of patients with and without chronic kidney disease.
News
Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD.
Drugs in the Pipeline
MK-2060 is an investigational monoclonal antibody designed to inhibit the activation of Factor XI and its ability to activate downstream proteins.
News
Study findings do not support initiation of uric acid-lowering therapy to prevent CKD.
News
This study raises important questions about the choice between lactated Ringer and saline.
News
Study findings highlight an "unmet need" for newer therapies.
